ArticleCancers2022

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma.

Yun Beom Sang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.